U.S. Luxury Stock News

NYSE:SAM
NYSE:SAMBeverage

Is Boston Beer Company (SAM) Priced Right After Mixed Craft And Hard Seltzer Demand Shifts

If you are wondering whether Boston Beer Company at around US$209.82 is a bargain or a value trap, you are not alone. That is exactly what this article tackles. The stock has returned 3.8% over the last 7 days and 3.3% over the last 30 days, although its 1 year return of a 19.0% decline and 5 year return of a 77.1% decline show a very different picture. Recent coverage has focused on how craft beer brands are competing for shelf space and how consumer tastes are shifting across beer, hard...
NYSE:ALSN
NYSE:ALSNMachinery

How Allison’s New Two-Unit Structure and Off-Highway Leadership Shift At Allison Transmission Holdings (ALSN) Has Changed Its Investment Story

Allison Transmission Holdings has reorganized into two business units, Allison Transmission and Allison Off-Highway Drive & Motion Systems, with Fred Bohley and newly appointed executive Craig Price leading the units and reporting to CEO David Graziosi. The hiring of Price from Dana’s Off-Highway business, alongside his long tenure in purchasing and supplier development, signals a push to tightly manage costs and extract efficiencies from the recently acquired operations. Next, we’ll examine...
NYSE:SHO
NYSE:SHOHotel and Resort REITs

Assessing Sunstone Hotel Investors (SHO) Valuation After Baird Downgrade And Steady Dividend Yield

Baird’s downgrade of Sunstone Hotel Investors (SHO) from Outperform to Neutral puts fresh attention on the REIT’s positioning versus peers, particularly given its consistent dividend history and current 3.82% yield. See our latest analysis for Sunstone Hotel Investors. The Baird downgrade comes after a mixed run for the stock, with a 1-day share price return of 1.08% and a 30-day share price return of 1.30%, set against a 1-year total shareholder return decline of 16.11%. Taken together, this...
NasdaqGM:ARCT
NasdaqGM:ARCTBiotechs

Does Arcturus Therapeutics (ARCT) JPM Conference Spotlight Clarify Its Long-Term Platform Credibility?

Arcturus Therapeutics Holdings Inc. recently presented at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at the Westin St. Francis Hotel in San Francisco, with Founder, President, CEO and Director Joseph E. Payne speaking. This high-profile conference appearance offered Arcturus a platform to showcase its pipeline and corporate story to a concentrated audience of healthcare-focused investors and industry peers. With this conference spotlight and recent share price...